Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul;34(7):1556-1571.
doi: 10.1007/s12325-017-0561-4. Epub 2017 May 25.

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin

Affiliations
Free PMC article
Review

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin

Akira Kawai et al. Adv Ther. .
Free PMC article

Abstract

Soft tissue sarcoma (STS) is a rare tumor with more than 50 histologic subtypes. Although treatment outcomes for patients with STS have improved greatly over the past few decades owing to the adoption of a multidisciplinary approach, patients with advanced disease have a poor prognosis. The development of anticancer drugs has been directed toward improving overall survival (OS). Doxorubicin monotherapy is currently the only standard option for the first-line treatment of STS. However, there is no standard therapy for second-line and later treatment at present. Since 2012, three anticancer drugs-pazopanib, trabectedin, and eribulin-have been approved in Japan for the second-line or later treatment of patients with advanced STS of any histologic subtype. However, the chemosensitivity of STS to each of these drugs varies by histologic subtype and their safety profiles differ; thus, histologic subtype and patient characteristics must be considered when determining optimal treatment. In this article, we review data from clinical studies related to the efficacy of all three drugs, including their effect on OS, and propose optimal treatment strategies for advanced STS by histologic subtype. In addition, with regard to the safety profiles, we highlight the key issues to be considered when selecting patients for treatment with pazopanib, trabectedin, or eribulin and ensuring their appropriate use, based on our combined clinical experience as specialists in the treatment of patients with STS. The proposed treatment strategies as well as treatment precautions based on clinical experience would benefit patients by maximizing the therapeutic effects and enhancing the proper use of these drugs.

Funding: Eisai Co., Ltd.

Keywords: Eribulin; Evidence-based medicine; Japan; Leiomyosarcoma; Liposarcoma; Optimal use; Pazopanib; Proper use; Soft tissue sarcoma; Trabectedin.

Figures

Fig. 1
Fig. 1
Treatment strategies for advanced STS in clinical practice. aNot approved for the treatment of STS in Japan. DTIC dacarbazine, DXR doxorubicin, GEM gemcitabine, DTX docetaxel

Similar articles

See all similar articles

Cited by 13 articles

See all "Cited by" articles

References

    1. Ducimetière F, Lurkin A, Ranchère-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6(8):e20294. doi: 10.1371/journal.pone.0020294. - DOI - PMC - PubMed
    1. Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CDM, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the Surveillance, Epidemiology and End Results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006;119:2922–2930. doi: 10.1002/ijc.22239. - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. doi: 10.3322/caac.21387. - DOI - PubMed
    1. Japanese Orthopaedic Association Committee on Musculoskeletal Tumor . Soft tissue tumor registry in Japan 2015. Tokyo: National Cancer Center; 2015.
    1. Schöffski P, Cornillie J, Wozniak A, Li H, Hompes D. Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease. Oncol Res Treat. 2014;37:355–362. doi: 10.1159/000362631. - DOI - PubMed
Feedback